GoodRx (GDRX) IPO Opens 39% Higher

Today's IPO for GoodRx (NASDAQ: GDRX) opened for trading at $46 after pricing 34,615,384 shares of its Class A common stock at a price to the public of $33.00 per share. Of the offered shares, 23,422,727 shares are being offered by GoodRx and 11,192,657 shares are being offered by certain of GoodRx’s existing selling shareholders

The underwriters have a 30-day option to purchase up to an additional 5,192,307 shares of Class A common stock from GoodRx at the initial public offering price less underwriting discounts and commission.

Morgan Stanley, Goldman Sachs & Co. LLC, J.P. Morgan and Barclays are acting as lead bookrunners for the offering. BofA Securities, Citigroup, Credit Suisse Securities (USA) LLC, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, and Evercore ISI are acting as additional bookrunners, and Citizens Capital Markets, KKR Capital Markets, LionTree Advisors, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus & Co., LLC and Ramirez & Co., Inc. are acting as co-managers for the offering.

GoodRx’s mission is to help Americans get the healthcare they need at a price they can afford. GoodRx’s leading digital platform for consumer healthcare products and services connects consumers with affordable and convenient prescriptions and medical care, including telehealth, mail order prescriptions, doctor visits, and lab tests. GoodRx has helped Americans save over $20 billion since 2011 and was the #1 most downloaded medical app in the last three years.

You May Also Be Interested In

• Jersey Mike's closes IPO at $23 per share on NYSE
• East West Ave Acquisition prices $100M IPO on Nasdaq
• SRX Global acquires shares in Jersey Mike's $1B IPO